Researchers say before idarucizumab was available, patients on dabigatran who needed emergency surgery were given purified clotting factors, which carry the risk of patients' clotting systems forming dangerous blood clots. Food and Drug Administration in October 2015 as the first medicine designed to reverse dabigatran. The new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks. Once the dabigatran is reversed, we can focus on taking care of the patient without worrying about the blood thinner.' 'Idarucizumab rapidly and completely reverses the effect of dabigatran in patients with brain hemorrhage. 'This is definitely good news,' Bernstein said. In patients who received two 2.5-gram of idarucizumab infusions in a 15-minute period, blood tests revealed that dabigatran's blood-thinning effect was 100 percent reversed in all 18 patients with brain bleed. This included 11 men and seven women (average age 79). Bernstein, M.D., Ph.D., lead study author and director of the stroke program at Northwestern Memorial Hospital in Chicago, Illinois.īernstein presented the results of 90 brain hemorrhage patients enrolled in the REVERSE-AD study. Idarucizumab (Praxbind) is an antibody that chemically binds and neutralizes the blood-thinning effects of dabigatran.Īn interim analysis of the first 90 patients in a study called RE-VERSE AD (REVERSal Effects of idarucizumab in patients on Active Dabigatran) showed that idarucizumab effectively reversed dabigatran's anticoagulant effects, said Richard A.

Patients on blood-thinning drugs, such as dabigatran (Pradaxa), who suffer a type of bleeding that occurs inside the skull (intracranial hemorrhage) are at high risk of complications or disability.

Dabigitran is prescribed to people with atrial fibrillation to prevent blood clots from forming in the heart and traveling to the brain causing a stroke.

Idarucizumab cost